Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity.

Hütter J, Rödig JV, Höper D, Seeberger PH, Reichl U, Rapp E, Lepenies B.

J Immunol. 2013 Jan 1;190(1):220-30. doi: 10.4049/jimmunol.1201060. Epub 2012 Dec 5.

2.

Impact of cultivation conditions on N-glycosylation of influenza virus a hemagglutinin produced in MDCK cell culture.

Rödig JV, Rapp E, Bohne J, Kampe M, Kaffka H, Bock A, Genzel Y, Reichl U.

Biotechnol Bioeng. 2013 Jun;110(6):1691-703. doi: 10.1002/bit.24834. Epub 2013 Feb 4.

PMID:
23297157
3.

Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin.

Schwarzer J, Rapp E, Hennig R, Genzel Y, Jordan I, Sandig V, Reichl U.

Vaccine. 2009 Jul 9;27(32):4325-36. doi: 10.1016/j.vaccine.2009.04.076. Epub 2009 May 14.

PMID:
19410619
4.

Impact of host cell line adaptation on quasispecies composition and glycosylation of influenza A virus hemagglutinin.

Roedig JV, Rapp E, Höper D, Genzel Y, Reichl U.

PLoS One. 2011;6(12):e27989. doi: 10.1371/journal.pone.0027989. Epub 2011 Dec 7.

5.

Addition of glycosylation to influenza A virus hemagglutinin modulates antibody-mediated recognition of H1N1 2009 pandemic viruses.

Job ER, Deng YM, Barfod KK, Tate MD, Caldwell N, Reddiex S, Maurer-Stroh S, Brooks AG, Reading PC.

J Immunol. 2013 Mar 1;190(5):2169-77. doi: 10.4049/jimmunol.1202433. Epub 2013 Jan 30.

6.

Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.

Montomoli E, Khadang B, Piccirella S, Trombetta C, Mennitto E, Manini I, Stanzani V, Lapini G.

Expert Rev Vaccines. 2012 May;11(5):587-94. doi: 10.1586/erv.12.24. Review.

PMID:
22827244
7.

Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines.

Nakowitsch S, Waltenberger AM, Wressnigg N, Ferstl N, Triendl A, Kiefmann B, Montomoli E, Lapini G, Sergeeva M, Muster T, Romanova JR.

Biotechnol J. 2014 Mar;9(3):405-14. doi: 10.1002/biot.201300225. Epub 2013 Dec 10. Erratum in: Biotechnol J. 2014 Apr;9(4):585.

PMID:
24323790
8.

Immune effects against influenza A virus and a novel DNA vaccine with co-expression of haemagglutinin- and neuraminidase-encoding genes.

Zhang W, Li W, Li Y, Li H, Wang B, Wang F, Zhu Y, Jiang Z, Zhong L, Li M.

J Med Microbiol. 2009 Jul;58(Pt 7):845-54. doi: 10.1099/jmm.0.006825-0. Epub 2009 Jun 4.

PMID:
19498203
9.

A Y161F Hemagglutinin Substitution Increases Thermostability and Improves Yields of 2009 H1N1 Influenza A Virus in Cells.

Wen F, Li L, Zhao N, Chiang MJ, Xie H, Cooley J, Webby R, Wang PG, Wan XF.

J Virol. 2018 Jan 2;92(2). pii: e01621-17. doi: 10.1128/JVI.01621-17. Print 2018 Jan 15.

PMID:
29118117
10.

MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation.

Genzel Y, Dietzsch C, Rapp E, Schwarzer J, Reichl U.

Appl Microbiol Biotechnol. 2010 Sep;88(2):461-75. doi: 10.1007/s00253-010-2742-9. Epub 2010 Jul 9.

PMID:
20617311
11.

Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines.

Shin D, Park KJ, Lee H, Cho EY, Kim MS, Hwang MH, Kim SI, Ahn DH.

Virus Res. 2015 Jun 2;204:40-6. doi: 10.1016/j.virusres.2015.04.005. Epub 2015 Apr 17.

PMID:
25892718
12.

Structural and evolutionary characteristics of HA, NA, NS and M genes of clinical influenza A/H3N2 viruses passaged in human and canine cells.

Zhirnov OP, Vorobjeva IV, Saphonova OA, Poyarkov SV, Ovcharenko AV, Anhlan D, Malyshev NA.

J Clin Virol. 2009 Aug;45(4):322-33. doi: 10.1016/j.jcv.2009.05.030.

PMID:
19546028
13.

Continuous cell lines as a production system for influenza vaccines.

Genzel Y, Reichl U.

Expert Rev Vaccines. 2009 Dec;8(12):1681-92. doi: 10.1586/erv.09.128. Review.

PMID:
19943763
14.

Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.

Medina J, Boukhebza H, De Saint Jean A, Sodoyer R, Legastelois I, Moste C.

Vaccine. 2015 Aug 20;33(35):4221-7. doi: 10.1016/j.vaccine.2015.06.112. Epub 2015 Jul 21.

PMID:
26206270
15.

Immunogenicity and safety of H1N1 influenza hemagglutinin protein expressed in a baculovirus system.

Na HN, Kim KH, Song MK, Park HL, Lee EY, Shim SH, Park S, Nam JH.

Microbiol Immunol. 2013 Sep;57(9):660-4. doi: 10.1111/1348-0421.12079.

16.

Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China.

Li C, Shao M, Cui X, Song Y, Li J, Yuan L, Fang H, Liang Z, Cyr TD, Li F, Li X, Wang J.

Biologicals. 2010 Mar;38(2):284-9. doi: 10.1016/j.biologicals.2009.12.004. Epub 2010 Jan 13.

PMID:
20074976
17.

Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation.

Saito T, Nakaya Y, Suzuki T, Ito R, Saito T, Saito H, Takao S, Sahara K, Odagiri T, Murata T, Usui T, Suzuki Y, Tashiro M.

J Med Virol. 2004 Oct;74(2):336-43.

PMID:
15332284
19.

Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.

Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.

Vaccine. 2012 Jun 22;30(30):4543-51. doi: 10.1016/j.vaccine.2012.03.061. Epub 2012 Apr 1.

PMID:
22475864
20.

N-glycan analysis by CGE-LIF: profiling influenza A virus hemagglutinin N-glycosylation during vaccine production.

Schwarzer J, Rapp E, Reichl U.

Electrophoresis. 2008 Nov;29(20):4203-14. doi: 10.1002/elps.200800042.

PMID:
18925582

Supplemental Content

Support Center